DICER1 Europe Launched to Advance Rare Cancer Research
A new organization has formed to connect families and researchers focused on the rare hereditary DICER1 syndrome.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you believe patient-led advocacy groups significantly help accelerate progress in medical research?
Patients and researchers have established DICER1 Europe to accelerate scientific progress on the hereditary disorder. The initiative aims to address data scarcity by launching a European patient registry for future multicenter studies.
Why it matters
The limited availability of patient data has historically hindered scientific understanding of this rare syndrome. This new organization seeks to unite families and research teams to ensure no family faces the condition in isolation.
Researchers have documented 2,009 cases of DICER1 syndrome worldwide, a hereditary disorder caused by gene mutations. The team at the Bellvitge Biomedical Research Institute has produced approximately twenty scientific publications on the condition.
The players
Bárbara Rivera
She leads the Rare Tumors Lab at the Bellvitge Biomedical Research Institute.
DICER1 Europe
This is a new organization formed to facilitate research and connect families affected by the syndrome.
Sosciathlon Solidarity Association
This organization recently raised funds to support medical research into the condition.
The details
DICER1 Europe integrates clinical care, genetic diagnosis, and specialized research to better identify new cases of the syndrome. Meanwhile, the Sosciathlon Solidarity Association recently contributed over €40,000 to support these ongoing research efforts.
Timeline
The IDIBELL research team began their competitive research projects in 2020.
The Sosciathlon Solidarity Association raised research funds last weekend.
The Big Picture
The formation of DICER1 Europe follows the research precedent set by the Bellvitge Biomedical Research Institute. This move extends the existing scientific framework to a wider, multicenter scope across the continent.
The creation of a European patient registry may eventually improve diagnostic speed and clinical care access for those with the syndrome. Families and patients can now connect with specialized research teams through the new organization.
The takeaway
Collaboration between patient advocacy groups and specialized laboratories remains essential for tackling rare diseases with limited documented cases. Increasing access to patient data is the primary hurdle currently facing global research efforts for DICER1 syndrome.
Further reading
Learn more about ongoing studies in the Cancer section.
Source note: This article includes information reported by Biotech-spain.
Live Poll
Do you believe patient-led advocacy groups significantly help accelerate progress in medical research?
